MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.

Lei LeiZhiming JiangGu ZhangQiaoyuan ChengHongyang Lu

Published in: World journal of surgical oncology (2018)

MGMT promoter methylation and 1p/19q co-deletion might not be the ideal biomarkers for TMZ treatment in TC/AC patients. Thus, the detection of MGMT promoter methylation and whether it can be used as a medication for TMZ in LCNEC patients necessitates investigation. Furthermore, 1p deletion could be a negative prognostic factor for LCNEC patients.

Keyphrases

prognostic factors
end stage renal disease
dna methylation
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
gene expression
emergency department
healthcare
stem cells
pulmonary hypertension
patient reported outcomes
bone marrow
smoking cessation
real time pcr